The Importance of Preparedness in the Community Oncology Setting
Jeff Patton, MD, explains the importance of preparedness in community oncology clinics as a World Cancer Day note.
Jeff Patton, MD, the CEO of OneOncology and executive board chair for Tennessee Oncology, explains the importance of preparedness in community oncology clinics as a World Cancer Day note.
During the coronavirus disease 2019 (COVID-19) pandemic, oncology practices have learned many lessons about how vulnerable patients with cancer are during times of crisis. Oncologists also learned how to best care for their patients with limited resources and sometimes, from a distance.
Although, it is believed that COVID-19 will soon be resolved, epidemics or pandemics can always occur, says Patton. It is important that community oncologists remember these times and be prepared for health crises in the future.
Read the full World Cancer Day interview with Jeff Patton, MD>>
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
